4-(苯基甲氧基)-1-萘磺酰氯 | 1048919-47-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-(苯基甲氧基)-1-萘磺酰氯
• 英文名称: 4-(benzyloxy)naphthalene-1-sulfonyl chloride
• 英文别名: 4-phenylmethoxynaphthalene-1-sulfonyl chloride
• CAS: 1048919-47-6
• 化学式: C₁₇H₁₃ClO₃S
• 分子量: 332.807
• InChiKey: QJRYVVVKYPNHOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  4-(苯基甲氧基)-1-萘磺酰氯 在 吡啶 、 palladium on activated charcoal 、 氢气 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成
  参考文献：
  名称：

  [EN] SMALL MOLECULE COMPOUNDS TARGETING PBX1 TRANSCRIPTIONAL COMPLEX
  [FR] COMPOSÉS À PETITES MOLÉCULES CIBLANT LE COMPLEXE TRANSCRIPTIONNEL PBX1

  摘要：

  公开号：

  WO2016172437A3
• 作为产物：
  描述：

  sodium 1-naphthol-4-sulfonate 在 氯化亚砜 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-(苯基甲氧基)-1-萘磺酰氯
  参考文献：
  名称：

  Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor

  摘要：

  Fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5) are mainly expressed in adipocytes and/or macrophages and play essential roles in energy metabolism and inflammation. When FABP4 function is diminished, FABP5 expression is highly increased possibly as a functional compensation. Dual FABP4/5 inhibitors are expected to provide beneficial synergistic effect on treating diabetes, atherosclerosis, and inflammation-related diseases. Starting from our previously reported selective FABP4 inhibitor 8, structural biology information was used to modulate the selectivity profile and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. Two compounds A16 and B8 were identified to show inhibitory activities against both FABP4/5 and good selectivity over FABP3, which could also reduce the level of forskolin-stimulated lipolysis in mature 3T3-L1 adipocytes. Compared with compound 8, these two compounds exhibited better anti-inflammatory effects in lipopolysaccharide-stimulated RAW264.7 murine macrophages, with decreased levels of pro-inflammatory cytokines TNF alpha and MCP-1 and apparently inhibited IKK/NF-kappa B pathway.

  DOI：

  10.1016/j.bmc.2019.07.031

文献信息

• SMALL MOLECULE INHIBITORS OF MCL-1 AND THE USES OF THEREOF
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20140235702A1

  公开（公告）日：2014-08-21

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

  这项发明涉及药物化学领域。具体而言，该发明涉及一类新型小分子，具有磺酰胺基-1-羟基萘结构，可作为Mcl-1蛋白酶抑制剂，并可用作治疗癌症和其他疾病的治疗剂。
• Design, Synthesis, and Evaluation of Naphthalene-Sulfonamide Antagonists of Human CCR8
  作者：Tracy J. Jenkins、Bing Guan、Mingshi Dai、Gang Li、Thomas E. Lightburn、Shan Huang、B. Scott Freeze、Douglas F. Burdi、Swanee Jacutin-Porte、Robert Bennett、Weirong Chen、Charles Minor、Shomir Ghosh、Christopher Blackburn、Kenneth M. Gigstad、Matthew Jones、Roland Kolbeck、Wei Yin、Sean Smith、Daniel Cardillo、Timothy D. Ocain、Geraldine C. Harriman

  DOI：10.1021/jm061118e

  日期：2007.2.8

  The design, synthesis, and structure-activity relationship development of naphthalene-derived human CCR8 antagonists is described. In vitro binding assay results of these investigations are reported, critical interactions of the antagonists with CCR8 are defined, and preliminary physicochemical and pharmacokinetic data for the naphthalene scaffold are presented.
• [EN] SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE MCL-1 ET LEURS UTILISATIONS
  申请人：UNIV MICHGIAN

  公开号：WO2013052943A3

  公开（公告）日：2013-06-20
• US9486422B2
  申请人：——

  公开号：US9486422B2

  公开（公告）日：2016-11-08
• Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor
  作者：Yulong He、Huixia Dou、Dingding Gao、Ting Wang、Mingming Zhang、Heyao Wang、Yingxia Li

  DOI：10.1016/j.bmc.2019.07.031

  日期：2019.10

  Fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5) are mainly expressed in adipocytes and/or macrophages and play essential roles in energy metabolism and inflammation. When FABP4 function is diminished, FABP5 expression is highly increased possibly as a functional compensation. Dual FABP4/5 inhibitors are expected to provide beneficial synergistic effect on treating diabetes, atherosclerosis, and inflammation-related diseases. Starting from our previously reported selective FABP4 inhibitor 8, structural biology information was used to modulate the selectivity profile and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. Two compounds A16 and B8 were identified to show inhibitory activities against both FABP4/5 and good selectivity over FABP3, which could also reduce the level of forskolin-stimulated lipolysis in mature 3T3-L1 adipocytes. Compared with compound 8, these two compounds exhibited better anti-inflammatory effects in lipopolysaccharide-stimulated RAW264.7 murine macrophages, with decreased levels of pro-inflammatory cytokines TNF alpha and MCP-1 and apparently inhibited IKK/NF-kappa B pathway.